Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Vorasidenib DDI with Oral Contraceptive in Healthy Females
NCT07235774Phase 1Completed
- Sponsor
- Servier
- Start
- Nov 2025
- Primary completion
- Mar 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of vorasidenib, sponsored by Servier. Primary endpoints: Maximum concentration at Day 25, Area under the plasma concentration versus time curve from time 0 to the last quantifiable concentration at Day 25 and 6 more. Started Nov 2025; status: completed.
02
Drugs
vorasidenib
Beyond the preview
Go deeper on NCT07235774.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07235774.